Glaxo Group Limited

Glaxosmithkline Intellectual Property Development Limited

Alfonso Mendoza Losana

Julia Castro Pichel

Silvia Gonzalez Del Valle

Esther Pilar Fernandez Velando

Raquel Fernandez Menendez

Lluis Ballell Pages

Maria Luisa León Diaz

Robert H Bates

David Barros Aguirre

Santiago Ramón García

Matthew James Wolfendale

Ruben Gonzalez Del Rio

Santiago RAMÓN GARCÍA

The present invention relates to or a pharmaceutically acceptable salt or ester prodrug thereof for use in the treatment of a mycobacterial infection or disease resulting from a mycobacterial infection, such as tuberculosis.

Sanfetrinem or a salt or ester thereof for use in treating mycobacterial infection

A compound of Formula (I) wherein: either X is N and Y is CRor X is C and Y is S; Z is selected from N and CH; Ris selected from H and Me; Ris selected from H, OH, OMe and Me; each Ris independently selected from Calkyl, F, Cl, Br, CFand NH; Ris selected from Me, CF, NOand CHF; Ris selected from H, Me and CHF; Ris selected from H and Me; and p is 0-3, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

(Pyrazol-3-yl)-1,3,4-thiadiazol-2-amine and (pyrazol-3-yl)-1,3,4-thiazol-2-amine compounds

Growing community of inventors

Madrid, Spain

Alfonso Mendoza Losana